Blood test for cervical cancer recurrence and treatment
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial uses a special blood test to look for tumor DNA in your blood to monitor for cervical cancer recurrence and help guide treatment decisions. It may help your doctor know if your cancer is coming back and choose the best treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and able to give written consent.
- You must have cervical cancer that is locally advanced, advanced, or has returned for the first time.
- You cannot have had any prior cancer treatment such as chemotherapy or radiation (for those with first recurrence, no treatment after the recurrence).
- You must have at least one tumor that can be measured on a scan.
- You must be willing to provide a tumor tissue sample (from a biopsy or surgery).
- You must be in generally good health (ECOG performance score of 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether simple blood tests can help predict how well first-line treatment works for cervical cancer that has come back or spread. It aims to improve future care by tracking changes in the blood over time.
This study tests whether DNA found in blood and urine can help detect cervical cancer and monitor it after treatment. If you’re newly diagnosed, these minimally invasive samples may help doctors follow your disease more easily over time.
This trial tests a combination of three drugs—camrelizumab (an immunotherapy that helps your immune system fight cancer), famitinib (a targeted therapy that blocks blood vessel growth to tumors), and standard chemotherapy—for cervical cancer that has come back or spread and cannot be removed with surgery or radiation. The goal is to see if this combination is safe and effective.
This trial checks how well cervical cancer responds to surgery, radiation, and chemotherapy by measuring HPV DNA and RNA in blood and cervical mucus. It aims to improve monitoring during treatment.
This study uses a simple blood test to look for tiny bits of cancer DNA after your treatment. It aims to see if this test can help predict whether the cancer might come back.
This study is looking for markers in the blood of people with cervical cancer that might help doctors choose the best treatment. It is a feasibility study, meaning it aims to find out if this approach works before a larger trial.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.